April 30, 2018 04:03 PM EDT

Eyeing Eylea's $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Brittany Meiling

Novartis is rolling out new data that build on its case for the company’s blockbuster hopeful RTH258, an investigational therapy that might carve away a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eyeing Eylea's $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Brittany Meiling

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Ionis’ treatment for a rare metabolic disorder

Eye­ing Eylea's $5B sales, No­var­tis touts sol­id 12-week dos­ing da­ta for its ri­val RTH258

Brittany Meiling

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Eyeing Eylea's $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

FDA approves Ionis’ treatment for a rare metabolic disorder